)
Overview
<ul>
<li>U.S. AI precision medicine firm’s Q1 revenue grew 36% yr/yr, slightly beating analyst expectations</li>
<li>Adjusted EBITDA loss for Q1 narrowed and beat analyst estimates</li>
<li>Company raised full-year 2026 revenue guidance to $1.59-$1.60 bln</li>
</ul>
Outlook
<ul>
<li>Tempus AI raises 2026 revenue guidance to $1.59-$1.60 bln</li>
<li>Company continues to expect 2026 Adjusted EBITDA of ~$65 mln</li>
<li>Tempus AI says strong demand for AI-driven diagnostics and data modeling expected to continue</li>
</ul>
Result Drivers
<ul>
<li>ONCOLOGY &amp; HEREDITARY VOLUME - Diagnostics revenue grew 34.7% yr/yr, driven by 28% Oncology volume growth and 54% Hereditary volume growth (7% after adjusting for Ambry acquisition timing)</li>
<li>MRD TESTING - MRD test volume rose ~500% yr/yr to ~6,500 tests, supporting Diagnostics segment growth</li>
<li>DATA &amp; APPLICATIONS MOMENTUM - Data and Applications revenue grew 40.5% yr/yr, with Insights (data licensing and modeling) up 44.1% Company press release:</li>
</ul>
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q1 Slight $348.12 $345.46
Revenue Beat* mln mln (15
Analysts
)
Q1 Net -$125.92
Income mln
Q1 Beat -$2.83 -$4.74
Adjusted mln mln (9
EBITDA Analysts
)
<h3>Q1 -$84.71</h3>
Income mln
from
Operatio
ns
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
<ul>
<li>The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 11 “strong buy” or “buy”, 7 “hold” and 1 “sell” or “strong sell”</li>
<li>The average consensus recommendation for the biotechnology &amp; medical research peer group is “buy”</li>
<li>Wall Street’s median 12-month price target for Tempus AI Inc is $80.00, about 43.3% above its May 4 closing price of $55.81 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</li>
</ul>

IDNA

Reuters

Tempus AI

VanEck Biotech ETF

iShares Genomics Immunology and Healthcare ETF

iShares US Healthcare Providers

ALPS Medical Breakthrough

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

Tradr 2X Long TEM Daily ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Thomson Reuters

London Stock Exchange Group plc

London Stock Exchange

LONDON STOCK EXCHANGE GROUP SPON ADS EACH REP 0.25 ORD

Tempus AI lifts 2026 revenue outlook